Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | 13.8% | 17.7% | 13.7% | 16.0% | 17.2% | 21.0% | 14.0% | (54.6%) | (20.2%) | (23.7%) | 3.4% | (0.6%) | 8.6% | 6.3% | 24.0% | 22.8% | 25.5% | 23.5% | 11.3% | (0.9%) |
Discover the top 20 best undervalued stocks to buy for Feb 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Feb 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Feb 2025.
As of today, Microsoft Corp's last 12-month Return on Equity (ROE) is 6.9%, based on the financial report for Sep 30, 2024 (Q3 2024). The average annual Return on Equity (ROE) for Amedisys, Inc. have been 11.9% over the past three years, and 15.3% over the past five years.
As of today, Amedisys, Inc.'s Return on Equity (ROE) is 6.9%, which is lower than industry median of 6.9%. It indicates that Amedisys, Inc.'s Return on Equity (ROE) is Bad.